Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01308840 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer
A Phase 2 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT01308840 is a Phase 2 study that has completed, run by University of Rochester. The registered enrollment target is 31 participants.
The verdict
NCT01308840, a Phase 2 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to determine disease response of GEMOX-Panitumumab (GEMOX-P) in KRAS/ BRAF wild-type, Stage IV, biliary tract and gallbladder cancer patients who have previously not received chemotherapy. This study will also examine the potential toxicities, progression-free and overall survival in this population.
Interventions
- DRUG oxaliplatin
- DRUG Panitumumab
- DRUG gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2010-12 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01308840
The ClinicalTrials.gov registry entry for NCT01308840 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which oxaliplatin is the first listed.
NCT01308840 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01308840 about?
NCT01308840 is a clinical study titled "Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer". The purpose of this study is to determine disease response of GEMOX-Panitumumab (GEMOX-P) in KRAS/ BRAF wild-type, Stage IV, biliary tract and gallbladder cancer patients who have previously not received chemotherapy. This study will also examine the potential toxicities, progression-free and overal...
What is the current status of trial NCT01308840?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2010-12. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01308840?
The interventions under investigation include: oxaliplatin (DRUG), Panitumumab (DRUG), gemcitabine (DRUG).
Who is sponsoring clinical trial NCT01308840?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.